IGC Pharma

IGC · NYSE American

$0.245+$0.003 (+1.24%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $0.242

IGC analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $4.08 (+1565.3% upside)

Low: $3.03
Now: $0.245
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

IGC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Aug 26, 2026	Maintains	Buy	$5.50 → $6.00	28%
Ascendiant Capital	Jun 8, 2026	Maintains	Buy	$5.25 → $5.50	28%
Ascendiant Capital	Apr 8, 2026	Maintains	Buy	$5.00 → $5.25	28%
Ascendiant Capital	Feb 23, 2026	Maintains	Buy	$4.75 → $5.00	28%
Ascendiant Capital	Dec 9, 2025	Maintains	Buy	$4.50 → $4.75	28%

The case for and against

Updated Oct 21, 2026

Bull case

IGC Pharma is supported by a compelling Alzheimer’s pipeline, led by IGC-AD1, which has shown promise in cell lines against plaques and tangles and produced clinically and statistically significant agitation reduction versus placebo in a March 2024 interim analysis. The investment case is strengthened by execution progress, with 100% enrollment of the 146-patient Phase 2 CALMA trial achieved in August and the company now within 6 additional randomizations of closure, while earlier April updates showed over 80% enrollment. With two major milestones expected in 2026, an attractive NPV-based valuation, and a billion-dollar market opportunity, the stock offers substantial upside if positive data continue to validate the program.

Bear case

IGC Pharma is an early/clinical-stage biotech with minimal revenue, posting just $0.3 million in both fiscal Q1 2026 and fiscal Q2 2026, while losses widened to $2.4 million and $2.9 million, respectively, underscoring a persistently weak earnings profile. Its Alzheimer’s pipeline may address a large unmet need, but the company remains dependent on unproven product candidates such as IGC-AD1, IGC-M3, IGC-1C, and TGR-63 to demonstrate safety, efficacy, and regulatory viability before any meaningful commercialization can occur. Balance sheet and liquidity risk, reimbursement uncertainty, and competitive and macroeconomic pressures further limit conviction, especially given the limited and transient effects of currently available Alzheimer’s drugs.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.